HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A metabolic phenotype based on mitochondrial ribosomal protein expression as a predictor of lymph node metastasis in papillary thyroid carcinoma.

Abstract
Metabolic reprogramming has been regarded as an essential component of malignant transformation. However, the clinical significance of metabolic heterogeneity remains poorly characterized. The aim of this study was to characterize metabolic heterogeneity in thyroid cancers via the analysis of the expression of mitochondrial ribosomal proteins (MRPs) and genes involved in oxidative phosphorylation (OxPhos), and investigate potential prognostic correlations. Gene set enrichment analysis (GSEA) verified by reverse transcription polymerase chain reaction and gene network analysis was performed using public repository data. Cross-sectional observational study was conducted to classify papillary thyroid cancer (PTC) by the expression of MRP L44 (MRPL44) messenger RNA (mRNA), and to investigate the clinicopathological features. GSEA clearly showed that the expression of OxPhos and MRP gene sets was significantly lower in primary thyroid cancer than in matched normal thyroid tissue. However, 8 of 49 primary thyroid tumors (16.3%) in the public repository did not show a reduction in OxPhos mRNA expression. Remarkably, strong positive correlations between MRPL44 expression and those of OxPhos and MRPs such as reduced nicotinamide adenine dinucleotide dehydrogenase (ubiquinone) 1 α subcomplex, 5; succinate dehydrogenase complex, subunit D; cytochrome c, somatic; adenosine triphosphate synthase, H+ transporting, mitochondrial Fo complex, subunit C1 (subunit 9); and MRP S5 (MRPS5) (P < 0.0001) were clearly denoted, suggesting that MRPL44 is a representative marker of OxPhos and MRP expressions. In laboratory experiments, metabolic heterogeneity in oxygen consumption, extracellular acidification rates (ECARs), and amounts of OxPhos complexes were consistently observed in BCPAP, TPC1, HTH-7, and XTC.UC1 cell lines. In PTCs, metabolic phenotype according to OxPhos amount defined by expression of MRPL44 mRNA was significantly related to lymph node metastasis (LNM) (P < 0.001). Furthermore, multivariate analysis clearly indicated that expression of MRPL44 is associated with an increased risk of lateral neck LNM (odds ratio 9.267, 95% confidence interval 1.852-46.371, P = 0.007). MRPL44 expression may be a representative marker of metabolic phenotype according to OxPhos amount and a useful predictor of LNM.
AuthorsJandee Lee, Mi-Youn Seol, Seonhyang Jeong, Cho Rok Lee, Cheol Ryong Ku, Sang-Wook Kang, Jong Ju Jeong, Dong Yeob Shin, Kee-Hyun Nam, Eun Jig Lee, Woong Youn Chung, Young Suk Jo
JournalMedicine (Medicine (Baltimore)) Vol. 94 Issue 2 Pg. e380 (Jan 2015) ISSN: 1536-5964 [Electronic] United States
PMID25590838 (Publication Type: Journal Article, Observational Study, Research Support, Non-U.S. Gov't)
Chemical References
  • Biomarkers, Tumor
  • Mitochondrial Proteins
  • RNA, Messenger
  • Ribosomal Proteins
  • mitochondrial ribosomal protein L44, human
Topics
  • Biomarkers, Tumor (genetics)
  • Carcinoma (genetics, metabolism, pathology)
  • Carcinoma, Papillary
  • Cell Transformation, Neoplastic (genetics)
  • Cellular Reprogramming
  • Confidence Intervals
  • Cross-Sectional Studies
  • Female
  • Gene Expression Profiling
  • Humans
  • Lymph Nodes (pathology)
  • Lymphatic Metastasis (diagnosis, genetics)
  • Male
  • Middle Aged
  • Mitochondrial Proteins (genetics)
  • Multivariate Analysis
  • Neck
  • Oxidative Phosphorylation
  • Prognosis
  • RNA, Messenger
  • Republic of Korea
  • Ribosomal Proteins (genetics)
  • Thyroid Cancer, Papillary
  • Thyroid Neoplasms (genetics, metabolism, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: